These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33930743)

  • 1. Structure-based virtual screening for novel potential selective inhibitors of class IIa histone deacetylases for cancer treatment.
    Elmezayen AD; Kemal Y
    Comput Biol Chem; 2021 Jun; 92():107491. PubMed ID: 33930743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
    Uba AI; Yelekçi K
    J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
    Hsu KC; Liu CY; Lin TE; Hsieh JH; Sung TY; Tseng HJ; Yang JM; Huang WJ
    Sci Rep; 2017 Jun; 7(1):3228. PubMed ID: 28607401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
    Ganai SA
    Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
    Gediya P; Parikh PK; Vyas VK; Ghate MD
    Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening.
    Sirous H; Campiani G; Calderone V; Brogi S
    Comput Biol Med; 2021 Oct; 137():104808. PubMed ID: 34478925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study.
    Huang D; Li X; Wei Y; Xiu Z
    Eur J Med Chem; 2012 Jun; 52():111-22. PubMed ID: 22465091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation.
    Khadempar S; Lotfi M; Haghiralsadat F; Saidijam M; Ghasemi N; Afshar S
    Comput Biol Med; 2023 Nov; 166():107518. PubMed ID: 37806058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment.
    Elmezayen AD; Al-Obaidi A; Yelekçi K
    J Mol Graph Model; 2021 Jul; 106():107937. PubMed ID: 34049193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
    Shetty MG; Pai P; Deaver RE; Satyamoorthy K; Babitha KS
    Pharmacol Res; 2021 Aug; 170():105695. PubMed ID: 34082029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
    Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S
    Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation.
    Pai P; Kumar A; Shetty MG; Kini SG; Krishna MB; Satyamoorthy K; Babitha KS
    J Mol Model; 2022 Apr; 28(5):119. PubMed ID: 35419753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective histone deacetylase inhibitors.
    Pan H; Cao J; Xu W
    Anticancer Agents Med Chem; 2012 Mar; 12(3):247-70. PubMed ID: 22263804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational identification of novel histone deacetylase inhibitors by docking based QSAR.
    Nair SB; Teli MK; Pradeep H; Rajanikant GK
    Comput Biol Med; 2012 Jun; 42(6):697-705. PubMed ID: 22521374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
    Gupta R; Ambasta RK; Kumar P
    Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.